Juki Ng

1.2k total citations
24 papers, 466 citations indexed

About

Juki Ng is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Juki Ng has authored 24 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Reproductive Medicine, 10 papers in Obstetrics and Gynecology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Juki Ng's work include Endometriosis Research and Treatment (15 papers), Uterine Myomas and Treatments (8 papers) and Ovarian function and disorders (5 papers). Juki Ng is often cited by papers focused on Endometriosis Research and Treatment (15 papers), Uterine Myomas and Treatments (8 papers) and Ovarian function and disorders (5 papers). Juki Ng collaborates with scholars based in United States, Germany and Ecuador. Juki Ng's co-authors include Cheri E. Klein, Kristof Chwalisż, Pamala A. Jacobson, John Rogosheske, Mohamad Shebley, Akshanth R. Polepally, Nael M. Mostafa, Voravit Ratanatharathorn, Joseph P. Uberti and Ahmed Nader and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Fertility and Sterility.

In The Last Decade

Juki Ng

23 papers receiving 457 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Juki Ng United States	12	261	223	99	65	55	24	466
Jolanta Żegarska Poland	10	13 0.0×	21 0.1×	118 1.2×	48 0.7×	23 0.4×	33	327
Jessie Ehrisman United States	15	172 0.7×	176 0.8×	1 0.0×	41 0.6×	44 0.8×	27	460
Natsuki Koike Japan	10	114 0.4×	200 0.9×		53 0.8×	60 1.1×	27	366
Divya Gupta United States	9	113 0.4×	157 0.7×		15 0.2×	20 0.4×	27	337
Luz Angela Torres-de la Roche Germany	13	74 0.3×	120 0.5×		14 0.2×	40 0.7×	57	436
Bachar Manav Greece	7	46 0.2×	93 0.4×		44 0.7×	45 0.8×	15	363
Chaoyan Yue China	12	64 0.2×	104 0.5×	1 0.0×	75 1.2×	71 1.3×	42	341
Vibeke Schiøler Denmark	12	112 0.4×	24 0.1×		52 0.8×	88 1.6×	20	431
Han Witjes United States	14	402 1.5×	35 0.2×		184 2.8×	400 7.3×	35	653
Jafaru Abu United Kingdom	11	179 0.7×	134 0.6×		29 0.4×	72 1.3×	22	460

Countries citing papers authored by Juki Ng

Since Specialization

Citations

This map shows the geographic impact of Juki Ng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juki Ng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juki Ng more than expected).

Fields of papers citing papers by Juki Ng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juki Ng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juki Ng. The network helps show where Juki Ng may publish in the future.

Co-authorship network of co-authors of Juki Ng

This figure shows the co-authorship network connecting the top 25 collaborators of Juki Ng. A scholar is included among the top collaborators of Juki Ng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juki Ng. Juki Ng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ng, Juki, et al.. (2025). Incidence of viral and non-viral etiologies of hepatocellular carcinoma (HCC) in the US over time by race and ethnicity.. Journal of Clinical Oncology. 43(16_suppl). 10551–10551. 1 indexed citations

Abou‐Alfa, Ghassan K., Mohamed Bouattour, Ann‐Lii Cheng, et al.. (2024). Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4190–TPS4190. 4 indexed citations

Snabes, Michael C., et al.. (2023). Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome. F&S Reports. 4(2). 206–212. 1 indexed citations

Kim, Jin Hee, James W. Thomas, Juki Ng, et al.. (2023). LONG-TERM THERAPY OF ELAGOLIX + ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY. Fertility and Sterility. 120(4). e62–e62.

Brown, Eric L., Robin Kroll, Juki Ng, et al.. (2023). Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas. Obstetrics and Gynecology. 142(5). 1068–1076. 1 indexed citations

Feldman, Robert, Yi‐Lin Chiu, Cheri E. Klein, & Juki Ng. (2021). Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women. Clinical Pharmacokinetics. 60(8). 1003–1013. 3 indexed citations

Stodtmann, Sven, Ahmed Nader, Akshanth R. Polepally, et al.. (2021). Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis. Clinical and Translational Science. 14(4). 1611–1619. 3 indexed citations

Polepally, Akshanth R., et al.. (2020). Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model. CPT Pharmacometrics & Systems Pharmacology. 9(8). 466–475. 3 indexed citations

Chiney, Manoj, Juki Ng, John P. Gibbs, & Mohamad Shebley. (2019). Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics. 59(5). 617–627. 21 indexed citations

10.

Shebley, Mohamad, Akshanth R. Polepally, Ahmed Nader, et al.. (2019). Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clinical Pharmacokinetics. 59(3). 297–309. 45 indexed citations

11.

Archer, David F., Juki Ng, Kristof Chwalisż, et al.. (2019). Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women. The Journal of Clinical Endocrinology & Metabolism. 105(3). 821–832. 17 indexed citations

12.

Nader, Ahmed, Akshanth R. Polepally, Mohan Liu, et al.. (2018). Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis. Clinical Pharmacokinetics. 57(10). 1295–1306. 23 indexed citations

13.

Gracia, Paulino Vigil‐De, et al.. (2018). Is there benefit to continue magnesium sulphate postpartum in women receiving magnesium sulphate before delivery? A randomised controlled study. BJOG An International Journal of Obstetrics & Gynaecology. 125(10). 1304–1311. 10 indexed citations

14.

Ng, Juki, et al.. (2017). Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women. The Journal of Clinical Endocrinology & Metabolism. 102(5). 1683–1691. 81 indexed citations

15.

Archer, David F., Elizabeth A. Stewart, Rita I. Jain, et al.. (2017). Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertility and Sterility. 108(1). 152–160.e4. 66 indexed citations

16.

Ng, Juki, et al.. (2011). Pharmacokinetics and Safety of the Lopinavir/Ritonavir Tablet 500/125 mg Twice Daily Coadministered With Efavirenz in Healthy Adult Participants. The Journal of Clinical Pharmacology. 52(8). 1248–1254. 3 indexed citations

17.

Ng, Juki, John Rogosheske, Juliet N. Barker, Daniel Weisdorf, & Pamala A. Jacobson. (2006). A Limited Sampling Model for Estimation of Total and Unbound Mycophenolic Acid (MPA) Area Under the Curve (AUC) in Hematopoietic Cell Transplantation (HCT). Therapeutic Drug Monitoring. 28(3). 394–401. 30 indexed citations

18.

Kerr, B M, Lisa Bauman, Juki Ng, et al.. (2006). O.106 Pharmakokinetics, safety, tolerability, and pharmacodynamics of the isatoribine oral prodrug ANA975 in a multidose phase 1 healthy volunteer study. Journal of Clinical Virology. 36. S31–S32. 2 indexed citations

19.

Jacobson, Pamala A., et al.. (2003). Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 9(5). 304–311. 38 indexed citations

20.

Jacobson, Pamala A., et al.. (2001). Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplantation. 28(8). 753–758. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact